David M. Nathan

David M. Nathan

Auto-generated profile, based on publicly available information

David M. Nathan

Diabetes Center, Massachusetts General Hospital and Harvard Medical School

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2013 in Diabetes Care
Verified
Journal Article
Open access
DNDavid M. Nathan
David M. Nathan
FGfor the DCCT/EDIC Research Group
for the DCCT/EDIC Research Group
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) was designed to test the glucose hypothesis and determine whether the complications of type 1 diabetes (T1DM) could be prevented or delayed. The Epidemiology of Diabetes Interventions and Complications (EDIC) observational follow-up determined the durability of the DCCT effects on the more-advanced stages of diabetes complications including cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: The DCCT (1982–1993) was a controlled clinical trial in 1,441 subjects with T1DM comparing intensive therapy (INT), aimed at achieving levels of glycemia as close to the nondiabetic range as safely possible, with conventional therapy (CON), which aimed to maintain safe asymptomatic glucose control. INT utilized three or more daily insulin injections or insulin pump therapy guided by self-monitored glucose. EDIC (1994–present) is an observational study of the DCCT cohort. RESULTS: The DCCT followed >99% of the cohort for a mean of 6.5 years and demonstrated a 35–76% reduction in the early stages of microvascular disease with INT, with a median HbA1c of 7%, compared with CONV, with a median HbA1c of 9%. The major adverse effect of INT was a threefold increased risk of hypoglycemia, which was not associated with a decline in cognitive function or quality of life. EDIC showed a durable effect of initial assigned therapies despite a loss of the glycemic separation (metabolic memory) and demonstrated that the reduction in early-stage complications during the DCCT translated into substantial reductions in severe complications and CVD. CONCLUSIONS: DCCT/EDIC has demonstrated the effectiveness of INT in reducing the long-term complications of T1DM and improving the prospects for a healthy life span.

16 November 2013 in Diabetes
Verified
Journal Article
Open access
DNDavid M. Nathan
David M. Nathan
MBMargaret Bayless
Margaret Bayless
PCPatricia Cleary
Patricia Cleary
SGSaul Genuth
Saul Genuth
RGRose Gubitosi-Klug
Rose Gubitosi-Klug
FGfor the DCCT/EDIC Research Group
for the DCCT/EDIC Research Group

6 February 2021 in Diabetologia
Verified
Journal Article
Closed access
PDF file
DNDavid M. Nathan
David M. Nathan

23 September 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
DNDavid M. Nathan
David M. Nathan
WHWilliam H. Herman
William H. Herman
MLMary E. Larkin
Mary E. Larkin
HKHeidi Krause-Steinrauf
Heidi Krause-Steinrauf
HAHiba Abou Assi
Hiba Abou Assi
ATA. Turchin
A. Turchin
OBJECTIVE: To determine whether the relationship between average glucose (AG) levels and hemoglobin A1c (HbA1c) differs across racial/ethnic groups. RESEARCH DESIGN AND METHODS: We performed a prospective substudy of GRADE, a comparative effectiveness randomized trial conducted in 36 centers in the U.S. A total of 1,454 of the 5,047 participants in the GRADE cohort, including 534 non-Hispanic White (NHW), 389 non-Hispanic Black (NHB), and 327 Hispanic White patients and 204 patients of other racial/ethnic backgrounds, were included in the substudy. Continuous glucose monitoring (CGM) performed for 10 days was used to calculate AG10. Immediately after CGM, HbA1c and glycated albumin were measured. Fasting plasma glucose (FPG) and glucose area under the curve (AUC) were derived from a 75-g oral glucose tolerance test. RESULTS: The relationship between AG10 and HbA1c was significantly different for NHB compared with NHW patients and those of other racial/ethnic groups. HbA1c levels were 0.2–0.6 percentage points higher in NHB than in NHW patients for AG10 levels from 100 to 250 mg/dL. For an HbA1c of 7%, AG10 was 11 mg/dL higher for NHW than for NHB patients. Similar findings were observed across races for relationships of FPG and AUC with HbA1c and for glucose measurements with glycated albumin levels. Differences in the relationship between AG10 and HbA1c across racial groups remained after adjustments for any demographic or other differences between racial/ethnic subgroups. CONCLUSIONS: The relationship between several measures of glucose with HbA1c and glycated albumin consistently differed across races. These findings should be considered in setting treatment goals and diagnostic levels.

1 July 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
HZHui Zheng
Hui Zheng
NWNancy Wei
Nancy Wei
DNDavid M. Nathan
David M. Nathan

31 July 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
DNDavid M. Nathan
David M. Nathan
JLJohn M. Lachin
John M. Lachin
David M. Nathan, John M. Lachin; History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Compl David M. Nathan, John M. Lachin; History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Compl